We improve human health by speeding up the creation of high-performance protein subunit antigens, and monoclonal antibodies.

Boost Biopharma’s innovative Rapid Antigen Deployment (RAD) Process is a game-changer in the field of vaccine development. It provides a solution to the challenges posed by rapidly evolving pathogens like SARS-CoV-2, the virus that causes COVID-19.

The RAD Process simplifies the creation of vaccines for new variants as they emerge. Since our vaccines are proteins they have several advantages over mRNA and other types of vaccines. For example, Boost’s vaccines can be designed to be safe, potent, highly targeted, thermally stable, locally manufacturable, and extremely low-cost.

Our team is entrepreneurial and resourceful, and we have achieved significant results to date. We own preclinical vaccine assets for COVID-19 (all variants of interest), Zika virus, Dengue Fever, West Nile virus, and Japanese Encephalitis. Boost also owns a high-performance SARS-CoV-2 monoclonal antibody in preclinical development.

Boost’s mission is to ‘do well by doing good’ and to create a legacy by making vaccines that improve human health for billions of people around the world.

We welcome a conversation.